The firm made the decision "based on both the near- and long-term potential of the company's unique, orally administered drug candidates for the prophylactic treatment of hereditary angioedema (HAE), a severely debilitating and potentially lethal orphan genetic disease," according to its research note issued Friday.
The stock was up 5.58% to $13.62 at 9:32 a.m.
Separately, TheStreet Ratings team rates BIOCRYST PHARMACEUTICALS INC as a "sell" with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation:
"We rate BIOCRYST PHARMACEUTICALS INC (BCRX) a SELL. This is driven by multiple weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. Among the areas we feel are negative, one of the most important has been generally deteriorating net income."
You can view the full analysis from the report here: BCRX Ratings Report